WT1 mRNA-loaded dendritic cell vaccine + temozolomide

This combination therapy consists of an autologous dendritic cell-based vaccine and the chemotherapy agent temozolomide, developed by the University Hospital, Antwerp for the treatment of newly diagnosed glioblastoma. The vaccine component is produced by loading a patient's own dendritic cells with messenger RNA (mRNA) encoding the Wilms' tumor 1 (WT1) protein, a tumor-associated antigen overexpressed in glioblastoma. These engineered dendritic cells are administered intradermally to stimulate a T-cell-mediated immune response against WT1-positive tumor cells. Temozolomide is an oral alkylating agent that provides standard-of-care cytotoxic chemotherapy by inducing DNA damage. The combination is currently being evaluated in the Phase I/II ADDIT-GLIO trial (NCT01291420) as an adjuvant treatment following surgical resection and chemoradiation.

Other names

WT1 mRNA-loaded DC vaccineWT-1 mRNA-loaded DC vaccineWT 1 mRNA-loaded DC vaccineADDIT-GLIO vaccineautologous Wilms' tumor 1 (WT1) messenger (m)RNA-loaded dendritic cell (DC) vaccination